FLT1 and Duchenne muscular dystrophy: Thus, anti-FLT1 antibody administration depleted sFLT1 levels and increased free serum VEGFA levels, which led to increased angiogenesis and reduced muscle pathology in mdx mice, providing a potential new pharmacological strategy for treatment of DMD.